81,340 Shares in Catalyst Pharmaceuticals, Inc. $CPRX Acquired by HighTower Advisors LLC

Key Points

• HighTower Advisors LLC has acquired 81,340 shares of Catalyst Pharmaceuticals, Inc., valued at approximately $1.97 million, representing a 0.07% ownership stake as per the latest SEC filing.
• Recent analyst ratings suggest mixed sentiment for Catalyst Pharmaceuticals, with Zacks and Wall Street Zen downgrading it to a "hold" rating while Cantor Fitzgerald upgraded it to a "strong-buy".
• Insider Preethi Sundaram sold 1,600 shares at an average price of $26.42, indicating a 3.75% decrease in their holdings, highlighting ongoing insider activity in the company's stock.

HighTower Advisors LLC bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 81,340 shares of the biopharmaceutical company's stock, valued at approximately $1,972,000. HighTower Advisors LLC owned about 0.07% of Catalyst Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after purchasing an additional 579 shares in the last quarter. Hohimer Wealth Management LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 3.6% during the 1st quarter. Hohimer Wealth Management LLC now owns 18,070 shares of the biopharmaceutical company's stock valued at $438,000 after purchasing an additional 629 shares in the last quarter. Vestcor Inc lifted its holdings in shares of Catalyst Pharmaceuticals by 3.0% during the 1st quarter. Vestcor Inc now owns 28,705 shares of the biopharmaceutical company's stock valued at $696,000 after purchasing an additional 840 shares in the last quarter. Illinois Municipal Retirement Fund lifted its holdings in shares of Catalyst Pharmaceuticals by 1.6% during the 1st quarter. Illinois Municipal Retirement Fund now owns 60,638 shares of the biopharmaceutical company's stock valued at $1,470,000 after purchasing an additional 929 shares in the last quarter. Finally, PDT Partners LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 5.2% during the 4th quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company's stock valued at $431,000 after purchasing an additional 1,030 shares in the last quarter. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Trading Up 1.0%

Shares of NASDAQ:CPRX traded up $0.21 during trading on Friday, hitting $20.59. 814,373 shares of the company were exchanged, compared to its average volume of 1,507,149. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of 12.48, a P/E/G ratio of 0.83 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.00 and a fifty-two week high of $26.58. The firm has a fifty day moving average price of $21.02 and a two-hundred day moving average price of $22.52.

Analysts Set New Price Targets

Several equities research analysts have commented on CPRX shares. Zacks Research cut Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Wall Street Zen cut Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, Catalyst Pharmaceuticals has an average rating of "Buy" and a consensus target price of $33.20.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 115,000 shares of the business's stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $20.28, for a total transaction of $2,332,200.00. Following the transaction, the insider owned 949,663 shares of the company's stock, valued at $19,259,165.64. The trade was a 10.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Richard J. Daly sold 22,970 shares of the business's stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $20.62, for a total value of $473,641.40. Following the transaction, the chief executive officer directly owned 226,794 shares in the company, valued at $4,676,492.28. This trade represents a 9.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold 167,894 shares of company stock worth $3,434,690 over the last 90 days. Company insiders own 10.40% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.